Marc Auriacombe - Publications

Affiliations: 
Université de Bordeaux, Talence, Nouvelle-Aquitaine, France 
Area:
Addiction Severity Index, Ecological Momentary Assessment, EMA, Craving, Feasibility, Conditioned stimuli, Cue reactivity, Substance use, Relapse

84 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Auriacombe M, Fournet L, Dupuy L, Micoulaud-Franchi JA, de Sevin E, Moriceau S, Baillet E, Alexandre JM, Serre F, Philip P. Effectiveness and Acceptance of a Smartphone-Based Virtual Agent Screening for Alcohol and Tobacco Problems and Associated Risk Factors During COVID-19 Pandemic in the General Population. Frontiers in Psychiatry. 12: 693687. PMID 34335332 DOI: 10.3389/fpsyt.2021.693687  1
2021 Fonseca F, Lenahan W, Dart RC, Papaseit E, Dargan PI, Wood DM, Guareschi M, Maremmani I, Auriacombe M, Farré M, Scherbaum N, Torrens M. Non-medical Use of Prescription Gabapentinoids (Gabapentin and Pregabalin) in Five European Countries. Frontiers in Psychiatry. 12: 676224. PMID 33995154 DOI: 10.3389/fpsyt.2021.676224  1
2021 Grall-Bronnec M, Guillou-Landreat M, Caillon J, Dubertret C, Romo L, Codina I, Chereau-Boudet I, Lancon C, Auriacombe M, Hardouin JB, Challet-Bouju G. Five-year follow-up on a sample of gamblers: predictive factors of relapse. Journal of Behavioral Addictions. PMID 33793415 DOI: 10.1556/2006.2021.00009  1
2021 Bahadoor R, Alexandre JM, Fournet L, Gellé T, Serre F, Auriacombe M. Inventory and Analysis of Controlled Trials of Mobile Phone Applications Targeting Substance Use Disorders: A Systematic Review. Frontiers in Psychiatry. 12: 622394. PMID 33692708 DOI: 10.3389/fpsyt.2021.622394  1
2020 Philip P, Dupuy L, Auriacombe M, Serre F, de Sevin E, Sauteraud A, Micoulaud-Franchi JA. Trust and acceptance of a virtual psychiatric interview between embodied conversational agents and outpatients. Npj Digital Medicine. 3: 2. PMID 33402675 DOI: 10.1038/s41746-019-0213-y  1
2020 Philip P, Dupuy L, Morin CM, de Sevin E, Bioulac S, Taillard J, Serre F, Auriacombe M, Micoulaud-Franchi JA. Smartphone-Based Virtual Agents to Help the General Population Concerned by Sleep Complaints During COVID-19 Confinement: A Feasibility Study. Journal of Medical Internet Research. PMID 33264099 DOI: 10.2196/24268  1
2020 Kervran C, Shmulewitz D, Serre F, Stohl M, Denis C, Hasin D, Auriacombe M. Item Response Theory analyses of DSM-5 substance use disorder criteria in French outpatient addiction clinic participants. How much is craving special? Drug and Alcohol Dependence. 212: 108036. PMID 32464467 DOI: 10.1016/J.Drugalcdep.2020.108036  1
2020 Philip P, Dupuy L, Auriacombe M, Serre F, de Sevin E, Sauteraud A, Micoulaud-Franchi JA. Trust and acceptance of a virtual psychiatric interview between embodied conversational agents and outpatients. Npj Digital Medicine. 3: 2. PMID 31934646 DOI: 10.1038/s41746-019-0213-y  1
2019 Benchebra L, Alexandre JM, Dubernet J, Fatséas M, Auriacombe M. [Gambling and Gaming disorders and physical health of players: A critical review of the literature]. Presse Medicale (Paris, France : 1983). PMID 31767247 DOI: 10.1016/J.Lpm.2019.10.014  1
2019 Kinouani S, Leflot C, Vanderkam P, Auriacombe M, Langlois E, Tzourio C. Motivations for using electronic cigarettes in young adults: A systematic review. Substance Abuse. 1-8. PMID 31638872 DOI: 10.1080/08897077.2019.1671937  1
2019 Auriacombe M, Roux P, Briand Madrid L, Kirchherr S, Kervran C, Chauvin C, Gutowski M, Denis C, Carrieri MP, Lalanne L, Jauffret-Roustide M. Impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol. Bmj Open. 9: e023683. PMID 30796121 DOI: 10.1136/Bmjopen-2018-023683  1
2018 Auriacombe M, Moriceau S, Serre F, Denis C, Micoulaud-Franchi JA, de Sevin E, Bonhomme E, Bioulac S, Fatseas M, Philip P. Development and validation of a virtual agent to screen tobacco and alcohol use disorders. Drug and Alcohol Dependence. 193: 1-6. PMID 30321739 DOI: 10.1016/J.Drugalcdep.2018.08.025  1
2018 Bouvard A, Dupuy M, Schweitzer P, Revranche M, Fatseas M, Serre F, Misdrahi D, Auriacombe M, Swendsen J. Feasibility and validity of mobile cognitive testing in patients with substance use disorders and healthy controls. The American Journal On Addictions. 27: 553-556. PMID 30260085 DOI: 10.1111/Ajad.12804  1
2018 Lemasson M, Rochette L, Galvão F, Poulet E, Lacroix A, Lecompte M, Auriacombe M, Patry S, Haesebaert F. Pertinence of Titration and Age-Based Dosing Methods for Electroconvulsive Therapy: An International Retrospective Multicenter Study. The Journal of Ect. PMID 29794554 DOI: 10.1097/Yct.0000000000000508  0.28
2018 Dupouy J, Vergnes A, Laporte C, Kinouani S, Auriacombe M, Oustric S, Rougé Bugat ME. Intensity of previous teaching but not diagnostic skills influences stigmatization of patients with substance use disorder by general practice residents. A vignette study among French final-year residents in general practice. The European Journal of General Practice. 24: 160-166. PMID 29792534 DOI: 10.1080/13814788.2018.1470239  1
2018 Fatseas M, Serre F, Swendsen J, Auriacombe M. Effects of anxiety and mood disorders on craving and substance use among patients with substance use disorder: An ecological momentary assessment study. Drug and Alcohol Dependence. 187: 242-248. PMID 29684892 DOI: 10.1016/J.Drugalcdep.2018.03.008  1
2018 Serre F, Fatseas M, Denis C, Swendsen J, Auriacombe M. Predictors of craving and substance use among patients with alcohol, tobacco, cannabis or opiate addictions: Commonalities and specificities across substances. Addictive Behaviors. PMID 29428330 DOI: 10.1016/J.Addbeh.2018.01.041  1
2017 Dematteis M, Auriacombe M, D'Agnone O, Somaini L, Szerman N, Littlewood R, Alam F, Alho H, Benyamina A, Bobes J, Daulouede JP, Leonardi C, Maremmani I, Torrens M, Walcher S, et al. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opinion On Pharmacotherapy. 18: 1987-1999. PMID 29183228 DOI: 10.1080/14656566.2017.1409722  1
2017 Dupouy J, Palmaro A, Fatséas M, Auriacombe M, Micallef J, Oustric S, Lapeyre-Mestre M. Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study. Annals of Family Medicine. 15: 355-358. PMID 28694272 DOI: 10.1370/Afm.2098  1
2017 Rolland B, Bouhassira D, Authier N, Auriacombe M, Martinez V, Polomeni P, Brousse G, Schwan R, Lack P, Bachellier J, Rostaing S, Bendimerad P, Vergne-Salle P, Dematteis M, Perrot S. [Misuse and dependence on prescription opioids: Prevention, identification and treatment]. La Revue De Medecine Interne. PMID 28214183 DOI: 10.1016/j.revmed.2016.12.024  0.01
2017 Bouvard A, Dupuy M, Chevalier M, Jakubiec L, Fatseas M, Serre F, Hurmic H, Revranche M, Misdrahi D, Auriacombe M, Swendsen J. Feasibility and validity of mobile cognitive testing in patients with substance use disorders European Neuropsychopharmacology. 27. DOI: 10.1016/S0924-977X(17)31890-4  1
2016 Fatséas M, Hurmic H, Serre F, Debrabant R, Daulouède JP, Denis C, Auriacombe M. Addiction severity pattern associated with adult and childhood Attention Deficit Hyperactivity Disorder (ADHD) in patients with addictions. Psychiatry Research. PMID 27842945 DOI: 10.1016/J.Psychres.2016.10.071  1
2016 Werb D, Garfein R, Kerr T, Davidson P, Roux P, Jauffret-Roustide M, Auriacombe M, Small W, Strathdee SA. A socio-structural approach to preventing injection drug use initiation: rationale for the PRIMER study. Harm Reduction Journal. 13: 25. PMID 27629248 DOI: 10.1186/S12954-016-0114-1  1
2016 Fatseas M, Kervran C, Auriacombe M. [Sleep disorders and addictions: Impact on quality of life and relapse vulnerability]. Presse Medicale (Paris, France : 1983). 45: 1164-1169. PMID 26970937 DOI: 10.1016/J.Lpm.2016.01.022  1
2016 Kaye S, Ramos-Quiroga JA, van de Glind G, Levin FR, Faraone SV, Allsop S, Degenhardt L, Moggi F, Barta C, Konstenius M, Franck J, Skutle A, Bu ET, Koeter MW, Demetrovics Z, ... ... Auriacombe M, et al. Persistence and Subtype Stability of ADHD Among Substance Use Disorder Treatment Seekers. Journal of Attention Disorders. PMID 26922805 DOI: 10.1177/1087054716629217  1
2016 Petry NM, Rehbein F, Gentile DA, Lemmens JS, Rumpf HJ, Mößle T, Bischof G, Tao R, Fung DS, Borges G, Auriacombe M, González-Ibáñez A, Tam P, O'Brien CP. Griffiths et al.'s comments on the international consensus statement of internet gaming disorder: furthering consensus or hindering progress? Addiction (Abingdon, England). 111: 175-8. PMID 26669531 DOI: 10.1111/Add.13189  1
2016 Denis C, Fatséas M, Beltran V, Serre F, Alexandre JM, Debrabant R, Daulouède JP, Auriacombe M. Usefulness and validity of the modified Addiction Severity Index: A focus on alcohol, drugs, tobacco, and gambling. Substance Abuse. 37: 168-75. PMID 26110463 DOI: 10.1080/08897077.2015.1036334  1
2016 Denis C, Fatséas M, Beltran V, Serre F, Alexandre JM, Debrabant R, Daulouède JP, Auriacombe M. Usefulness and validity of the modified Addiction Severity Index: A focus on alcohol, drugs, tobacco, and gambling Substance Abuse. 37: 168-175. DOI: 10.1080/08897077.2015.1036334  1
2015 Skutle A, Bu ETH, Jellestad FK, van Emmerik-van Oortmerssen K, Dom G, Verspreet S, Carpentier PJ, Ramos-Quiroga JA, Franck J, Konstenius M, Kaye S, Demetrovics Z, Barta C, Fatséas M, Auriacombe M, et al. Early developmental, temperamental and educational problems in 'substance use disorder' patients with and without ADHD. Does ADHD make a difference? Addictive Behaviors Reports. 2: 13-18. PMID 29531989 DOI: 10.1016/J.Abrep.2015.03.001  1
2015 Kervran C, Fatséas M, Serre F, Taillard J, Beltran V, Leboucher J, Debrabant R, Alexandre JM, Daulouède JP, Philip P, Auriacombe M. Association between morningness/eveningness, addiction severity and psychiatric disorders among individuals with addictions. Psychiatry Research. 229: 1024-30. PMID 26250146 DOI: 10.1016/J.Psychres.2015.05.026  1
2015 Wapp M, van de Glind G, van Emmerik-van Oortmerssen K, Dom G, Verspreet S, Carpentier PJ, Ramos-Quiroga JA, Skutle A, Bu ET, Franck J, Konstenius M, Kaye S, Demetrovics Z, Barta C, Fatséas M, ... Auriacombe M, et al. Risk Factors for Borderline Personality Disorder in Treatment Seeking Patients with a Substance Use Disorder: An International Multicenter Study. European Addiction Research. 21: 188-94. PMID 25832736 DOI: 10.1159/000371724  1
2015 Fatseas M, Serre F, Alexandre JM, Debrabant R, Auriacombe M, Swendsen J. Craving and substance use among patients with alcohol, tobacco, cannabis or heroin addiction: a comparison of substance- and person-specific cues. Addiction (Abingdon, England). 110: 1035-42. PMID 25688760 DOI: 10.1111/Add.12882  1
2015 Serre F, Fatseas M, Swendsen J, Auriacombe M. Ecological momentary assessment in the investigation of craving and substance use in daily life: a systematic review. Drug and Alcohol Dependence. 148: 1-20. PMID 25637078 DOI: 10.1016/J.Drugalcdep.2014.12.024  1
2015 Demaret I, Quertemont E, Litran G, Magoga C, Deblire C, Auriacombe M, Dubois N, Roubaix JD, Charlier C, Lemaître A, Ansseau M, Senbanjo R, Strang J, Fernández-Aranda F, Jiménez-Murcia S, et al. Front & Back Matter European Addiction Research. 21. DOI: 10.1159/000342515  1
2015 Skutle A, Bu ETH, Jellestad FK, van Emmerik-van Oortmerssen K, Dom G, Verspreet S, Carpentier PJ, Ramos-Quiroga JA, Franck J, Konstenius M, Kaye S, Demetrovics Z, Barta C, Fatséas M, Auriacombe M, et al. Early developmental, temperamental and educational problems in 'substance use disorder' patients with and without ADHD: Does ADHD make a difference? Addictive Behaviors Reports. 2: 13-18. DOI: 10.1016/j.abrep.2015.03.001  1
2014 Auriacombe M, Denis C, Fatséas M. Commentary on Scharkow etal. (2014): Welcomed and yet to come. Are we looking at what we are looking for? Addiction. 109: 1918-1919. PMID 25297961 DOI: 10.1111/Add.12723  1
2014 Lofwall MR, Martin J, Tierney M, Fatséas M, Auriacombe M, Lintzeris N. Buprenorphine diversion and misuse in outpatient practice. Journal of Addiction Medicine. 8: 327-32. PMID 25221985 DOI: 10.1097/Adm.0000000000000029  1
2014 Petry NM, Rehbein F, Gentile DA, Lemmens JS, Rumpf HJ, Mößle T, Bischof G, Tao R, Fung DS, Borges G, Auriacombe M, GonzálezIbáñez A, Tam P, O'Brien CP. Moving internet gaming disorder forward: A reply. Addiction (Abingdon, England). 109: 1412-3. PMID 25103100 DOI: 10.1111/Add.12653  1
2014 Petry NM, Rehbein F, Gentile DA, Lemmens JS, Rumpf HJ, Mößle T, Bischof G, Tao R, Fung DS, Borges G, Auriacombe M, GonzálezIbáñez A, Tam P, O'Brien CP. Internet gaming and addiction: a reply to King & Delfabbro. Addiction (Abingdon, England). 109: 1567-8. PMID 24724947 DOI: 10.1111/Add.12549  1
2014 Petry NM, Rehbein F, Gentile DA, Lemmens JS, Rumpf HJ, Mößle T, Bischof G, Tao R, Fung DS, Borges G, Auriacombe M, González Ibáñez A, Tam P, O'Brien CP. An international consensus for assessing internet gaming disorder using the new DSM-5 approach. Addiction (Abingdon, England). 109: 1399-406. PMID 24456155 DOI: 10.1111/Add.12457  1
2014 van de Glind G, Konstenius M, Koeter MW, van Emmerik-van Oortmerssen K, Carpentier PJ, Kaye S, Degenhardt L, Skutle A, Franck J, Bu ET, Moggi F, Dom G, Verspreet S, Demetrovics Z, Kapitány-Fövény M, ... ... Auriacombe M, et al. Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: results from an international multi-center study exploring DSM-IV and DSM-5 criteria. Drug and Alcohol Dependence. 134: 158-66. PMID 24156882 DOI: 10.1016/J.Drugalcdep.2013.09.026  1
2014 van Emmerik-van Oortmerssen K, van de Glind G, Koeter MW, Allsop S, Auriacombe M, Barta C, Bu ET, Burren Y, Carpentier PJ, Carruthers S, Casas M, Demetrovics Z, Dom G, Faraone SV, Fatseas M, et al. Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study. Addiction (Abingdon, England). 109: 262-72. PMID 24118292 DOI: 10.1111/Add.12370  1
2014 Petry NM, Blanco C, Auriacombe M, Borges G, Bucholz K, Crowley TJ, Grant BF, Hasin DS, O'Brien C. An overview of and rationale for changes proposed for pathological gambling in DSM-5. Journal of Gambling Studies / Co-Sponsored by the National Council On Problem Gambling and Institute For the Study of Gambling and Commercial Gaming. 30: 493-502. PMID 23526033 DOI: 10.1007/S10899-013-9370-0  1
2014 Petry NM, Rehbein F, Gentile DA, Lemmens JS, Rumpf HJ, Mößle T, Bischof G, Tao R, Fung DSS, Borges G, Auriacombe M, Gonzálezibáñez A, Tam P, O'Brien CP. Internet gaming and addiction: A reply to King & Delfabbro Addiction. 109: 1567-1568. DOI: 10.1111/add.12549  1
2014 Petry NM, Rehbein F, Gentile DA, Lemmens JS, Rumpf HJ, Mößle T, Bischof G, Tao R, Fung DSS, Borges G, Auriacombe M, González Ibáñez A, Tam P, O'Brien CP. An international consensus for assessing internet gaming disorder using the new DSM-5 approach Addiction. 109: 1399-1406. DOI: 10.1111/add.12457  1
2013 Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF. DSM-5 criteria for substance use disorders: recommendations and rationale. The American Journal of Psychiatry. 170: 834-51. PMID 23903334 DOI: 10.1176/Appi.Ajp.2013.12060782  1
2013 Denis C, Lavie E, Fatseas M, Auriacombe M. WITHDRAWN: Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings The Cochrane Database of Systematic Reviews. 6. PMID 23780682  1
2013 Denis C, Fatseas M, Lavie E, Auriacombe M. WITHDRAWN: Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings The Cochrane Database of Systematic Reviews. 6. PMID 23780681 DOI: 10.1002/14651858.Cd005194.Pub3  1
2013 van de Glind G, van den Brink W, Koeter MW, Carpentier PJ, van Emmerik-van Oortmerssen K, Kaye S, Skutle A, Bu ET, Franck J, Konstenius M, Moggi F, Dom G, Verspreet S, Demetrovics Z, Kapitány-Fövény M, ... ... Auriacombe M, et al. Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients. Drug and Alcohol Dependence. 132: 587-96. PMID 23660242 DOI: 10.1016/J.Drugalcdep.2013.04.010  1
2013 Hasin DS, Auriacombe M, Borges G, Bucholz K, Budney A, Crowley T, Grant BF, O'Brien C, Petry NM, Schuckit M, Wall MM. The DSM-5 field trials and reliability of alcohol use disorder. The American Journal of Psychiatry. 170: 442-3. PMID 23545795 DOI: 10.1176/Appi.Ajp.2013.13010032  1
2013 Bouju G, Hardouin J-, Grall-Bronnec M, Vénisse J-, Romo L, Legauffre C, Dubertret C, Codina I, Valleur M, Auriacombe M, Fatséas M, Alexandre J-, Llorca P-, Chéreau-Boudet I, Lançon C, et al. Les joueurs de poker : un profil différent des autres joueurs ? European Psychiatry. 28: 6. DOI: 10.1016/J.Eurpsy.2013.09.015  1
2013 Grall-Bronnec M, Bouju G, Guilleux A, Vénisse J-, Hardouin J-, Romo L, Legauffre C, Dubertret C, Codina I, Valleur M, Auriacombe M, Fatséas M, Alexandre J-, Llorca P-, Chéreau-Boudet I, et al. Ces français qui jouent, du plaisir à l’excès. À partir d’une étude multicentrique portant sur 628 joueurs European Psychiatry. 28: 6-6. DOI: 10.1016/J.Eurpsy.2013.09.014  1
2013 Beaufort DGd, Sesay M, Stinus L, Thiebaut R, Auriacombe M, Dousset V. P 4. Cerebral blood flow modulation by transcutaneous cranial electrical stimulation with Limoge’s current Clinical Neurophysiology. 124. DOI: 10.1016/J.Clinph.2013.04.083  1
2012 Serre F, Fatseas M, Debrabant R, Alexandre JM, Auriacombe M, Swendsen J. Ecological momentary assessment in alcohol, tobacco, cannabis and opiate dependence: a comparison of feasibility and validity. Drug and Alcohol Dependence. 126: 118-23. PMID 22647899 DOI: 10.1016/J.Drugalcdep.2012.04.025  1
2012 Fatseas M, Debrabant R, Auriacombe M. The diagnostic accuracy of attention-deficit/hyperactivity disorder in adults with substance use disorders. Current Opinion in Psychiatry. 25: 219-25. PMID 22449768 DOI: 10.1097/Yco.0B013E3283523D7C  1
2012 Denis C, Fatséas M, Beltran V, Bonnet C, Picard S, Combourieu I, Daulouède JP, Auriacombe M. Validity of the self-reported drug use section of the Addiction Severity Index and associated factors used under naturalistic conditions. Substance Use & Misuse. 47: 356-63. PMID 22216906 DOI: 10.3109/10826084.2011.640732  1
2012 Malivert M, Fatséas M, Denis C, Langlois E, Auriacombe M. Effectiveness of therapeutic communities: a systematic review. European Addiction Research. 18: 1-11. PMID 21997500 DOI: 10.1159/000331007  1
2012 Fatseas M, Denis C, Serre F, Dubernet J, Daulouède JP, Auriacombe M. Change in HIV-HCV risk-taking behavior and seroprevalence among opiate users seeking treatment over an 11-year period and harm reduction policy. Aids and Behavior. 16: 2082-90. PMID 21983799 DOI: 10.1007/S10461-011-0054-4  1
2012 Denis C, Fatséas M, Auriacombe M. Analyses related to the development of DSM-5 criteria for substance use related disorders: 3. An assessment of Pathological Gambling criteria Drug and Alcohol Dependence. 122: 22-27. PMID 21962725 DOI: 10.1016/J.Drugalcdep.2011.09.006  1
2012 Gense de Beaufort D, Sesay M, Stinus L, Thiebaut R, Auriacombe M, Dousset V. Cerebral blood flow modulation by transcutaneous cranial electrical stimulation with Limoge's current. Journal of Neuroradiology. Journal De Neuroradiologie. 39: 167-75. PMID 21835468 DOI: 10.1016/J.Neurad.2011.06.001  1
2011 Fatseas M, Denis C, Massida Z, Verger M, Franques-Rénéric P, Auriacombe M. Cue-induced reactivity, cortisol response and substance use outcome in treated heroin dependent individuals. Biological Psychiatry. 70: 720-7. PMID 21741031 DOI: 10.1016/J.Biopsych.2011.05.015  1
2010 Fatséas M, Denis C, Lavie E, Auriacombe M. Relationship between anxiety disorders and opiate dependence- A systematic review of the literature. Implications for diagnosis and treatment Journal of Substance Abuse Treatment. 38: 220-230. PMID 20116963 DOI: 10.1016/J.Jsat.2009.12.003  1
2009 Le Bec PY, Fatséas M, Denis C, Lavie E, Auriacombe M. [Cannabis and psychosis: search of a causal link through a critical and systematic review]. L'Encephale. 35: 377-85. PMID 19748375 DOI: 10.1016/J.Encep.2008.02.012  1
2009 Fatséas M, Lavie E, Denis C, Auriacombe M. Self-perceived motivation for benzodiazepine use and behavior related to benzodiazepine use among opiate-dependent patients Journal of Substance Abuse Treatment. 37: 407-411. PMID 19339146 DOI: 10.1016/J.Jsat.2009.03.006  1
2009 Lavie E, Fatséas M, Denis C, Auriacombe M. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: Correlates of use, abuse and dependence Drug and Alcohol Dependence. 99: 338-344. PMID 18824311 DOI: 10.1016/J.Drugalcdep.2008.07.017  1
2008 Lavie E, Fatséas M, Daulouède JP, Denis C, Dubernet J, Cattan L, Auriacombe M. Comparison of prescriber evaluations and patient-directed self-reports in office-based practice for buprenorphine treatment of opiate-dependent individuals in France, 2002. Patient Preference and Adherence. 2: 369-78. PMID 19920984 DOI: 10.2147/Ppa.S4136  1
2007 Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Current Psychiatry Reports. 9: 358-64. PMID 17915074 DOI: 10.1007/S11920-007-0046-2  1
2006 Denis C, Lavie E, Fatséas M, Auriacombe M. Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings Cochrane Database of Systematic Reviews (Online). 3. PMID 16856093 DOI: 10.1002/14651858.Cd005336.Pub2  1
2006 Denis C, Fatséas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. The Cochrane Database of Systematic Reviews. CD005194. PMID 16856084 DOI: 10.1002/14651858.CD005194.pub2  1
2006 Fatséas M, Lavie E, Denis C, Franques-Rénéric P, Tignol J, Auriacombe M. [Benzodiazepine withdrawal in subjects on opiate substitution treatment]. Presse Medicale (Paris, France : 1983). 35: 599-606. PMID 16614601 DOI: 10.1016/S0755-4982(06)74647-4  1
2006 Tignol J, Martin-Guehl C, Aouizerate B, Grabot D, Auriacombe M. Social phobia and premature ejaculation: a case-control study. Depression and Anxiety. 23: 153-7. PMID 16502416 DOI: 10.1002/Da.20159  1
2005 Encrenaz G, Rondeau V, Messiah A, Auriacombe M. Examining the influence of drop-outs in a follow-up of maintained opiate users. Drug and Alcohol Dependence. 79: 303-10. PMID 16102374 DOI: 10.1016/J.Drugalcdep.2005.01.021  1
2005 Weinrieb RM, Auriacombe M, Lynch KG, Lewis JD. Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opinion On Drug Safety. 4: 337-44. PMID 15794724 DOI: 10.1517/14740338.4.2.337  0.01
2005 Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine dependence management among benzodiazepine users in outpatient settings Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.Cd005194  1
2004 Auriacombe M, Fatséas M, Dubernet J, Daulouède JP, Tignol J. French field experience with buprenorphine. The American Journal On Addictions. 13: S17-28. PMID 15204673 DOI: 10.1080/10550490490440780  1
2003 Mangon E, Simon S, Franques-Rénéric P, Auriacombe M. [Development of diagnosis criteria for physical activity abuse and dependence: a qualitative study]. Annales De Medecine Interne. 154: S33-42. PMID 14760225  1
2003 Weinrieb RM, Auriacombe M, Lynch KG, Chang KM, Lewis JD. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. The Journal of Clinical Psychiatry. 64: 1502-10. PMID 14728113 DOI: 10.4088/Jcp.V64N1215  0.01
2003 Cotto E, Neau D, Cransac-Neau M, Auriacombe M, Pellegrin JL, Ragnaud JM, Fillet AM, Belnard M, Fleury H, Lafon ME. Borna disease virus RNA in immunocompromised patients in southwestern France. Journal of Clinical Microbiology. 41: 5577-81. PMID 14662943 DOI: 10.1128/Jcm.41.12.5577-5581.2003  0.01
2003 Auriacombe M, Fatseas M, Franques-Rénéric P, Daulouède JP, Tignol J. [Substitution therapy in drug addictions]. La Revue Du Praticien. 53: 1327-34. PMID 12920942  1
2002 Loustauneau A, Auriacombe M, Daulouede JP, Tignol J. [Is buprenorphine a potential alternative to methadone for treating pregnant drug users? Inventory of clinical data in the literature]. Annales De Medecine Interne. 153: 2S31-6. PMID 12518080  1
2000 Auriacombe M, Rénéric JP, Usandizaga D, Gomez F, Combourieu I, Tignol J. Post-ECT agitation and plasma lactate concentrations. The Journal of Ect. 16: 263-7. PMID 11005048 DOI: 10.1097/00124509-200009000-00007  1
1997 Auriacombe M, Reneric JP, Le Moal M. Animal models of anhedonia. Psychopharmacology. 134: 337-8; discussion 37. PMID 9452166 DOI: 10.1007/S002130050459  1
1990 Stinus L, Auriacombe M, Tignol J, Limoge A, Le Moal M. Transcranial electrical stimulation with high frequency intermittent current (Limoge's) potentiates opiate-induced analgesia: blind studies. Pain. 42: 351-63. PMID 2250924 DOI: 10.1016/0304-3959(90)91148-C  1
1990 Auriacombe M, Tignol J, Le Moal M, Stinus L. Transcutaneous electrical stimulation with Limoge current potentiates morphine analgesia and attenuates opiate abstinence syndrome. Biological Psychiatry. 28: 650-6. PMID 2173629 DOI: 10.1016/0006-3223(90)90451-7  1
Show low-probability matches.